The core of the present invention concerns the invention of a method and device for plug-and-play of concentration (
potency) and
avidity parameters utilizing a continuous gradient of ligand density applied to a
biosensor surface. Previous studies have investigated the humoral
antibody response and strength of binding to specific SARS-CoV-2 proteins.
Surface plasmon resonance imaging (SPRi) was used to measure the binding strength of IgG, IgM, and IgA to the
receptor binding domain and nucleocapsid (RBD / NCP) of SARS-CoV-2 in the serum of 119 COVID-19 patients. Interestingly, in contrast to the
antibody titer, the
avidity (increasing off-rate) decreased with increasing severity. The present invention measures concentration and affinity / activity parameters in a plug-and-play manner in a
single test. Ligand density is a key parameter that has a large
impact on the value of the off-rate. A 10-fold mismatch is easily obtained. Not only the off-rate but also the on-rate at the immobilized ligand density needs to be measured, but in that case the effective concentration also needs to be known. The core of the invention is the application of a continuous gradient to the sensor surface to determine
antibody titer and
avidity, providing a constant but low R max Measure the avidity parameter with a high R value max The goal of the dual
gradient method is to measure the concentration of antibodies at a single value. In this way, antibodies against the infection can be determined for each patient, especially to determine and predict the severity of COVID 19. The dual
gradient method can be applied to measure two targets simultaneously.